Celyad Oncology receives non-compliance letter from Nasdaq

Stock Information for Celyad Oncology SA

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Celyad Oncology SA

Celyad Oncology announces receipt of Nasdaq delisting notice
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
Celyad Oncology announces receipt of Nasdaq notice
Celyad Oncology appoints Georges Rawadi as its new CEO
Celyad Oncology reports full year 2022 financial results and recent business highlights
Celyad Oncology to announce full year 2022 financial results and host conference call
Celyad Oncology announces non-cash impairment
REPEAT -- Celyad Oncology SA - Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.